

Helicobacter Pylori Market: Epidemiology, Industry Trends, Share, Size, Growth, Opportunity, and Forecast 2024-2034

<https://marketpublishers.com/r/HF4030ED2D35EN.html>

Date: May 2024

Pages: 129

Price: US\$ 6,499.00 (Single User License)

ID: HF4030ED2D35EN

Abstracts

The 7 major helicobacter pylori markets reached a value of US\$ 3,480.9 Million in 2023. Looking forward, IMARC Group expects the 7MM to reach US\$ 3,891.7 Million by 2034, exhibiting a growth rate (CAGR) of 1.02% during 2024-2034.

The helicobacter pylori market has been comprehensively analyzed in IMARC's new report titled "Helicobacter Pylori Market: Epidemiology, Industry Trends, Share, Size, Growth, Opportunity, and Forecast 2024-2034". Helicobacter pylori is a type of bacteria that infects the stomach lining, resulting in chronic inflammation and damage to the protective mucus layer. The ailment can spread through close contact with an infected person's saliva, vomit, or fecal matter. It can also be transmitted through the consumption of contaminated food or water. Some common symptoms of this disease include abdominal pain and discomfort, bloating, nausea, vomiting, lack of appetite, frequent burping, unexplained weight loss, heartburn or acid reflux, etc. In rare cases, individuals suffering from the illness might experience gastrointestinal bleeding, which can lead to the passage of black, tarry stools. The diagnosis of Helicobacter pylori can be made through a comprehensive evaluation of the patient's characteristic features, medical history, and physical examination. The healthcare professional may conduct various diagnostic investigations, including stool antigen analysis, urea breath test, blood antibody workup, etc., to detect the presence of bacteria and confirm the diagnosis. Furthermore, an endoscopy with tissue biopsy is recommended to assess the severity of inflammation or any other underlying conditions.

The increasing cases of bacterial diseases, which are transmissible through close personal contact, such as kissing or sharing utensils and food with an infected person, are primarily driving the Helicobacter pylori market. In addition to this, the rising

prevalence of poor hygiene conditions that can contribute to the spread of the bacterium is also creating a positive outlook for the market. Moreover, the widespread adoption of combination therapy, which involves a proton pump inhibitor along with two antibiotics, usually clarithromycin and amoxicillin or metronidazole, to eradicate the pathogen and promote healing of the affected stomach lining, is further bolstering the market growth. Apart from this, the inflating application of polymerase chain reaction (PCR) technique, since it amplifies specific DNA sequences, thereby allowing rapid detection or quantification of even small amounts of the bacterial genome, is acting as another significant growth-inducing factor. Additionally, the emerging popularity of injectable antibiotics on account of their several benefits over oral medications, such as optimal drug absorption and faster symptom relief, is expected to drive the *Helicobacter pylori* market during the forecast period.

IMARC Group's new report provides an exhaustive analysis of the *Helicobacter pylori* market in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan. This includes treatment practices, in-market, and pipeline drugs, share of individual therapies, market performance across the seven major markets, market performance of key companies and their drugs, etc. The report also provides the current and future patient pool across the seven major markets. According to the report the United States has the largest patient pool for *Helicobacter pylori* and also represents the largest market for its treatment. Furthermore, the current treatment practice/algorithm, market drivers, challenges, opportunities, reimbursement scenario and unmet medical needs, etc. have also been provided in the report. This report is a must-read for manufacturers, investors, business strategists, researchers, consultants, and all those who have any kind of stake or are planning to foray into the *Helicobacter pylori* market in any manner.

Time Period of the Study

Base Year: 2023

Historical Period: 2018-2023

Market Forecast: 2024-2034

Countries Covered

United States

Germany

France

United Kingdom

Italy
Spain
Japan

Analysis Covered Across Each Country

Historical, current, and future epidemiology scenario

Historical, current, and future performance of the Helicobacter pylori market

Historical, current, and future performance of various therapeutic categories in the market

Sales of various drugs across the Helicobacter pylori market

Reimbursement scenario in the market

In-market and pipeline drugs

Competitive Landscape:

This report also provides a detailed analysis of the current Helicobacter pylori marketed drugs and late-stage pipeline drugs.

In-Market Drugs

Drug Overview

Mechanism of Action

Regulatory Status

Clinical Trial Results

Drug Uptake and Market Performance

Late-Stage Pipeline Drugs

Drug Overview

Mechanism of Action

Regulatory Status

Clinical Trial Results

Drug Uptake and Market Performance

*Kindly note that the drugs in the above table only represent a partial list of marketed/pipeline drugs, and the complete list has been provided in the report.

Key Questions Answered in this Report:

Market Insights

How has the Helicobacter pylori market performed so far and how will it perform in the coming years?

What are the markets shares of various therapeutic segments in 2023 and how are they expected to perform till 2034?

What was the country-wise size of the Helicobacter pylori market across the seven major markets in 2023 and what will it look like in 2034?

What is the growth rate of the Helicobacter pylori market across the seven major markets and what will be the expected growth over the next ten years?

What are the key unmet needs in the market?

Epidemiology Insights

What is the number of prevalent cases (2018-2034) of Helicobacter pylori across the seven major markets?

What is the number of prevalent cases (2018-2034) of Helicobacter pylori by age across the seven major markets?

What is the number of prevalent cases (2018-2034) of Helicobacter pylori by gender across the seven major markets?

How many patients are diagnosed (2018-2034) with Helicobacter pylori across the seven major markets?

What is the size of the Helicobacter pylori patient pool (2018-2023) across the seven major markets?

What would be the forecasted patient pool (2024-2034) across the seven major markets?

What are the key factors driving the epidemiological trend of Helicobacter pylori?

What will be the growth rate of patients across the seven major markets?

Helicobacter Pylori: Current Treatment Scenario, Marketed Drugs and Emerging Therapies

What are the current marketed drugs and what are their market performance?

What are the key pipeline drugs and how are they expected to perform in the coming years?

How safe are the current marketed drugs and what are their efficacies?

How safe are the late-stage pipeline drugs and what are their efficacies?

What are the current treatment guidelines for Helicobacter pylori drugs across the seven major markets?

Who are the key companies in the market and what are their market shares?

What are the key mergers and acquisitions, licensing activities, collaborations, etc.

related to the Helicobacter pylori market?

What are the key regulatory events related to the Helicobacter pylori market?

What is the structure of clinical trial landscape by status related to the Helicobacter pylori market?

What is the structure of clinical trial landscape by phase related to the Helicobacter pylori market?

What is the structure of clinical trial landscape by route of administration related to the Helicobacter pylori market?

Contents

1 PREFACE

2 SCOPE AND METHODOLOGY

- 2.1 Objectives of the Study
- 2.2 Stakeholders
- 2.3 Data Sources
 - 2.3.1 Primary Sources
 - 2.3.2 Secondary Sources
- 2.4 Market Estimation
 - 2.4.1 Bottom-Up Approach
 - 2.4.2 Top-Down Approach
- 2.5 Forecasting Methodology

3 EXECUTIVE SUMMARY

4 HELICOBACTER PYLORI - INTRODUCTION

- 4.1 Overview
- 4.2 Regulatory Process
- 4.3 Epidemiology (2018-2023) and Forecast (2024-2034)
- 4.4 Market Overview (2018-2023) and Forecast (2024-2034)
- 4.5 Competitive Intelligence

5 HELICOBACTER PYLORI - DISEASE OVERVIEW

- 5.1 Introduction
- 5.2 Symptoms and Diagnosis
- 5.3 Pathophysiology
- 5.4 Causes and Risk Factors
- 5.5 Treatment

6 PATIENT JOURNEY

7 HELICOBACTER PYLORI - EPIDEMIOLOGY AND PATIENT POPULATION

- 7.1 Epidemiology - Key Insights

- 7.2 Epidemiology Scenario - Top 7 Markets
 - 7.2.1 Epidemiology Scenario (2018-2023)
 - 7.2.2 Epidemiology Forecast (2024-2034)
 - 7.2.3 Epidemiology by Age (?2018-2034?)
 - 7.2.4 Epidemiology by Gender (?2018-2034?)
 - 7.2.5 Diagnosed Cases (?2018-2034?)
 - 7.2.6 Patient Pool/Treated Cases (?2018-2034?)
- 7.3 Epidemiology Scenario - United States
 - 7.3.1 Epidemiology Scenario (2018-2023)
 - 7.3.2 Epidemiology Forecast (2024-2034)
 - 7.3.3 Epidemiology by Age (?2018-2034?)
 - 7.3.4 Epidemiology by Gender (?2018-2034?)
 - 7.3.5 Diagnosed Cases (?2018-2034?)
 - 7.3.6 Patient Pool/Treated Cases (?2018-2034?)
- 7.4 Epidemiology Scenario - Germany
 - 7.4.1 Epidemiology Scenario (2018-2023)
 - 7.4.2 Epidemiology Forecast (2024-2034)
 - 7.4.3 Epidemiology by Age (?2018-2034?)
 - 7.4.4 Epidemiology by Gender (?2018-2034?)
 - 7.4.5 Diagnosed Cases (?2018-2034?)
 - 7.4.6 Patient Pool/Treated Cases (?2018-2034?)
- 7.5 Epidemiology Scenario - France
 - 7.5.1 Epidemiology Scenario (2018-2023)
 - 7.5.2 Epidemiology Forecast (2024-2034)
 - 7.5.3 Epidemiology by Age (?2018-2034?)
 - 7.5.4 Epidemiology by Gender (?2018-2034?)
 - 7.5.5 Diagnosed Cases (?2018-2034?)
 - 7.5.6 Patient Pool/Treated Cases (?2018-2034?)
- 7.6 Epidemiology Scenario - United Kingdom
 - 7.6.1 Epidemiology Scenario (2018-2023)
 - 7.6.2 Epidemiology Forecast (2024-2034)
 - 7.6.3 Epidemiology by Age (?2018-2034?)
 - 7.6.4 Epidemiology by Gender (?2018-2034?)
 - 7.6.5 Diagnosed Cases (?2018-2034?)
 - 7.6.6 Patient Pool/Treated Cases (?2018-2034?)
- 7.7 Epidemiology Scenario - Italy
 - 7.7.1 Epidemiology Scenario (2018-2023)
 - 7.7.2 Epidemiology Forecast (2024-2034)
 - 7.7.3 Epidemiology by Age (?2018-2034?)

- 7.7.4 Epidemiology by Gender (?2018-2034?)
- 7.7.5 Diagnosed Cases (?2018-2034?)
- 7.7.6 Patient Pool/Treated Cases (?2018-2034?)
- 7.8 Epidemiology Scenario - Spain
 - 7.8.1 Epidemiology Scenario (2018-2023)
 - 7.8.2 Epidemiology Forecast (2024-2034)
 - 7.8.3 Epidemiology by Age (?2018-2034?)
 - 7.8.4 Epidemiology by Gender (?2018-2034?)
 - 7.8.5 Diagnosed Cases (?2018-2034?)
 - 7.8.6 Patient Pool/Treated Cases (?2018-2034?)
- 7.9 Epidemiology Scenario - Japan
 - 7.9.1 Epidemiology Scenario (2018-2023)
 - 7.9.2 Epidemiology Forecast (2024-2034)
 - 7.9.3 Epidemiology by Age (?2018-2034?)
 - 7.9.4 Epidemiology by Gender (?2018-2034?)
 - 7.9.5 Diagnosed Cases (?2018-2034?)
 - 7.9.6 Patient Pool/Treated Cases (?2018-2034?)

8 HELICOBACTER PYLORI - TREATMENT ALGORITHM, GUIDELINES, AND MEDICAL PRACTICES

- 8.1 Guidelines, Management and Treatment
- 8.2 Treatment Algorithm

9 HELICOBACTER PYLORI - UNMET NEEDS

10 HELICOBACTER PYLORI - KEY ENDPOINTS OF TREATMENT

11 HELICOBACTER PYLORI - MARKETED PRODUCTS

- 11.1 List of Helicobacter Pylori Marketed Drugs Across the Top 7 Markets
 - 11.1.1 Voquezna Triple Pak (vonoprazan/amoxicillin/clarithromycin) - Phathom Pharmaceuticals
 - 11.1.1.1 Drug Overview
 - 11.1.1.2 Mechanism of Action
 - 11.1.1.3 Regulatory Status
 - 11.1.1.4 Clinical Trial Results
 - 11.1.1.5 Sales Across Major Markets
 - 11.1.2 Voquezna Dual Pak (vonoprazan/amoxicillin) - Phathom Pharmaceuticals

- 11.1.2.1 Drug Overview
- 11.1.2.2 Mechanism of Action
- 11.1.2.3 Regulatory Status
- 11.1.2.4 Clinical Trial Results
- 11.1.2.5 Sales Across Major Markets
- 11.1.3 Talicia (Amoxicillin/omeprazole/rifabutin) - RedHill Biopharma
 - 11.1.3.1 Drug Overview
 - 11.1.3.2 Mechanism of Action
 - 11.1.3.3 Regulatory Status
 - 11.1.3.4 Clinical Trial Results
 - 11.1.3.5 Sales Across Major Markets
- 11.1.4 Prilosec (Omeprazole) - AstraZeneca/Mitsubishi Tanabe Pharma Corporation
 - 11.1.4.1 Drug Overview
 - 11.1.4.2 Mechanism of Action
 - 11.1.4.3 Regulatory Status
 - 11.1.4.4 Clinical Trial Results
 - 11.1.4.5 Sales Across Major Markets
- 11.1.5 Nexium (Esomeprazole) - AstraZeneca
 - 11.1.5.1 Drug Overview
 - 11.1.5.2 Mechanism of Action
 - 11.1.5.3 Regulatory Status
 - 11.1.5.4 Clinical Trial Results
 - 11.1.5.5 Sales Across Major Markets

Kindly note that the above only represents a partial list of marketed drugs, and the complete list has been provided in the report.

12 HELICOBACTER PYLORI - PIPELINE DRUGS

- 12.1 List of Helicobacter Pylori Pipeline Drugs Across the Top 7 Markets
 - 12.1.1 Drug Name – Company Name
 - 12.1.1.1 Drug Overview
 - 12.1.1.2 Mechanism of Action
 - 12.1.1.3 Clinical Trial Results
 - 12.1.1.4 Safety and Efficacy
 - 12.1.1.5 Regulatory Status

Kindly note that the complete list of pipeline drugs has been provided in the report.

13. HELICOBACTER PYLORI - ATTRIBUTE ANALYSIS OF KEY MARKETED AND PIPELINE DRUGS

14. HELICOBACTER PYLORI – CLINICAL TRIAL LANDSCAPE

- 14.1 Drugs by Status
- 14.2 Drugs by Phase
- 14.3 Drugs by Route of Administration
- 14.4 Key Regulatory Events

15 HELICOBACTER PYLORI - MARKET SCENARIO

- 15.1 Market Scenario - Key Insights
- 15.2 Market Scenario - Top 7 Markets
 - 15.2.1 Helicobacter Pylori - Market Size
 - 15.2.1.1 Market Size (2018-2023)
 - 15.2.1.2 Market Forecast (2024-2034)
 - 15.2.2 Helicobacter Pylori - Market Size by Therapies
 - 15.2.2.1 Market Size by Therapies (2018-2023)
 - 15.2.2.2 Market Forecast by Therapies (2024-2034)
- 15.3 Market Scenario - United States
 - 15.3.1 Helicobacter Pylori - Market Size
 - 15.3.1.1 Market Size (2018-2023)
 - 15.3.1.2 Market Forecast (2024-2034)
 - 15.3.2 Helicobacter Pylori - Market Size by Therapies
 - 15.3.2.1 Market Size by Therapies (2018-2023)
 - 15.3.2.2 Market Forecast by Therapies (2024-2034)
 - 15.3.3 Helicobacter Pylori - Access and Reimbursement Overview
- 15.4 Market Scenario - Germany
 - 15.4.1 Helicobacter Pylori - Market Size
 - 15.4.1.1 Market Size (2018-2023)
 - 15.4.1.2 Market Forecast (2024-2034)
 - 15.4.2 Helicobacter Pylori - Market Size by Therapies
 - 15.4.2.1 Market Size by Therapies (2018-2023)
 - 15.4.2.2 Market Forecast by Therapies (2024-2034)
 - 15.4.3 Helicobacter Pylori - Access and Reimbursement Overview
- 15.5 Market Scenario - France
 - 15.5.1 Helicobacter Pylori - Market Size
 - 15.5.1.1 Market Size (2018-2023)
 - 15.5.1.2 Market Forecast (2024-2034)
 - 15.5.2 Helicobacter Pylori - Market Size by Therapies

- 15.5.2.1 Market Size by Therapies (2018-2023)
- 15.5.2.2 Market Forecast by Therapies (2024-2034)
- 15.5.3 Helicobacter Pylori - Access and Reimbursement Overview
- 15.6 Market Scenario - United Kingdom
 - 15.6.1 Helicobacter Pylori - Market Size
 - 15.6.1.1 Market Size (2018-2023)
 - 15.6.1.2 Market Forecast (2024-2034)
 - 15.6.2 Helicobacter Pylori - Market Size by Therapies
 - 15.6.2.1 Market Size by Therapies (2018-2023)
 - 15.6.2.2 Market Forecast by Therapies (2024-2034)
 - 15.6.3 Helicobacter Pylori - Access and Reimbursement Overview
- 15.7 Market Scenario - Italy
 - 15.7.1 Helicobacter Pylori - Market Size
 - 15.7.1.1 Market Size (2018-2023)
 - 15.7.1.2 Market Forecast (2024-2034)
 - 15.7.2 Helicobacter Pylori - Market Size by Therapies
 - 15.7.2.1 Market Size by Therapies (2018-2023)
 - 15.7.2.2 Market Forecast by Therapies (2024-2034)
 - 15.7.3 Helicobacter Pylori - Access and Reimbursement Overview
- 15.8 Market Scenario - Spain
 - 15.8.1 Helicobacter Pylori - Market Size
 - 15.8.1.1 Market Size (2018-2023)
 - 15.8.1.2 Market Forecast (2024-2034)
 - 15.8.2 Helicobacter Pylori - Market Size by Therapies
 - 15.8.2.1 Market Size by Therapies (2018-2023)
 - 15.8.2.2 Market Forecast by Therapies (2024-2034)
 - 15.8.3 Helicobacter Pylori - Access and Reimbursement Overview
- 15.9 Market Scenario - Japan
 - 15.9.1 Helicobacter Pylori - Market Size
 - 15.9.1.1 Market Size (2018-2023)
 - 15.9.1.2 Market Forecast (2024-2034)
 - 15.9.2 Helicobacter Pylori - Market Size by Therapies
 - 15.9.2.1 Market Size by Therapies (2018-2023)
 - 15.9.2.2 Market Forecast by Therapies (2024-2034)
 - 15.9.3 Helicobacter Pylori - Access and Reimbursement Overview

16 HELICOBACTER PYLORI - RECENT EVENTS AND INPUTS FROM KEY OPINION LEADERS

17 HELICOBACTER PYLORI MARKET - SWOT ANALYSIS

17.1 Strengths

17.2 Weaknesses

17.3 Opportunities

17.4 Threats

18 HELICOBACTER PYLORI MARKET – STRATEGIC RECOMMENDATIONS

19 APPENDIX

I would like to order

Product name: Helicobacter Pylori Market: Epidemiology, Industry Trends, Share, Size, Growth, Opportunity, and Forecast 2024-2034

Product link: <https://marketpublishers.com/r/HF4030ED2D35EN.html>

Price: US\$ 6,499.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

info@marketpublishers.com

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/HF4030ED2D35EN.html>

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name:
Last name:
Email:
Company:
Address:
City:
Zip code:
Country:
Tel:
Fax:
Your message:

****All fields are required**

Customer signature _____

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at <https://marketpublishers.com/docs/terms.html>

To place an order via fax simply print this form, fill in the information below and fax the completed form to +44 20 7900 3970

